Rocket Pharmaceuticals (RCKT) Non-Current Debt (2014)

Rocket Pharmaceuticals' (RCKT) quarterly Non-Current Debt came in at $2.6 million in Q4 2014.

Rocket Pharmaceuticals (RCKT) Non-Current Debt (2014) Analysis & Trends

Rocket Pharmaceuticals has disclosed Non-Current Debt across 1 years of filings, most recently posting $2.6 million for Q4 2014.

Non-Current Debt for Q4 2014 came in at $2.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2014 was $2.6 million (changed N/A YoY), and the FY2014 annual result was $2.6 million, changed N/A from the prior year.
Non-Current Debt came in at $2.6 million for Q4 2014 at Rocket Pharmaceuticals.
In the past five years, Non-Current Debt ranged from a high of $2.6 million in Q4 2014 to a low of $2.6 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	319.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	-
9	Abivax	95.45 Bn	95.45 Bn	-	-
10	Rocket Pharmaceuticals	296.03 Mn	296.03 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2014	2.55 Mn
Dec 31, 2014	2.55 Mn